Pfizer and Moderna both received FDA authorization for mRNA vaccines, and phase 3 data efficacy was sky high.
Related Articles
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
3 Healthcare Stocks to Keep an Eye On
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
Is Pfizer Stock a Buy Now?
Is Hims & Hers Health Stock a Buy Now?
468%
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Stock Advisor Returns
468%
S&P 500 Returns
124%
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Cumulative Growth of a $10,000 Investment in Stock Advisor
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Our Most Popular Articles
3 Lesser-Known Medicare Rules Everyone Should Be Aware Of
Meet the Nearly 9%-Yielding Dividend Stock Wall Street Hates That I've Quadrupled My Position in Recently
Amazon Gets Sued by the FTC. Here's What I'm Doing With My Shares.
Down More Than 20% in a Week, This Elite Dividend Stock is Looking Like a Screaming Bargain
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.